Clinical and genetic bases of hypertensive nephrosclerosis. NEFROSEN Study;Bases clínicas y genéticas de la nefroesclerosis hipertensiva. Estudio NEFROSEN

Nefrologia

Volumn 30, Issue 6, 2010, Pages 687-697

  Ojea, B Diez ^a   Marin R ^b   Coto, E ^c   Vega, F Fernández ^c   Navascués, R Álvarez ^c   Fresnedo, G Fernández ^d   De Salinas, A PobesMartínez ^e   Laurés, A Suárez ^f   Monteavaro, C García ^e   Gorostidi, M ^c   Sanchez E ^c   Arias, M ^d   Ortega, F ^c  

^a HOSPITAL VALLE DEL NALÓN   (Spain)

^b Centro Medico de Asturias   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e HOSPITAL SAN AGUSTÍN   (Spain)

^f HOSPITAL DE CABUEÑES   (Spain)

Author keywords

Chronic kidney disease; Essential hypertension; Hypertensive nephrosclerosis; MYH9 gene

Indexed keywords

MOLECULAR MOTOR; MYH9 PROTEIN, HUMAN; MYOSIN HEAVY CHAIN;

ADULT; AGED; ARTICLE; CAUCASIAN; CHRONIC KIDNEY FAILURE; COMORBIDITY; COMPARATIVE STUDY; DISEASE COURSE; ECONOMICS; ETHNOLOGY; FEMALE; FINANCIAL MANAGEMENT; GENETIC PREDISPOSITION; GENETICS; HUMAN; HYPERTENSION; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY (TOPIC); NEPHROSCLEROSIS; RETROSPECTIVE STUDY; RISK FACTOR; SPAIN;

ADULT; AGED; COMORBIDITY; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MOLECULAR MOTOR PROTEINS; MULTICENTER STUDIES AS TOPIC; MYOSIN HEAVY CHAINS; NEPHROSCLEROSIS; RESEARCH SUPPORT AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; SPAIN;

EID: 78649980124     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2010.Jul.10372     Document Type: Article

References (49)

1. Luft FC. Hypertensive nephrosclerosis: update. Curr Opin Nephrol Hypertens 2004;13:147-54.
2. Freedman BI, Iskandar SS, Appel RG. The link between hypertension and nephrosclerosis. Am J Kidney Dis 1995;25:207-21.
3. Marín R, Gorostidi M, Fernández-Vega F, Álvarez-Navascués R. Systemic and glomerular hypertension and progression of chronic renal disease: the dilemma of nephrosclerosis. Kidney Int Suppl 2005;(99):S52-S56.
4. Luke RG. Hypertensive nephrosclerosis: pathogenesis and prevalence. Essential hypertension is an important cause of end-stage renal disease. Nephrol Dial Transplant 1999;14:2271-78.
5. Marcantoni C, Ma LJ, Federspiel C, Fogo AB. Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int 2002;62:172-80.
6. Hill GS, Heudes D, Jacquot C, Gauthier E, Bariéty J. Morphometric evidence for impairment of renal autoregulation in advanced essential hypertension. Kidney Int 2006;69:823-31.
7. Keller G, Zimmer G, Mall G, Ritz E. Amann K. Nephron number in patients with primary hypertension. N Engl J Med 2003;348:101-8.
8. Hsu CY. Does non-malignant hypertension cause renal insufficiency? Evidence-based perspective. Curr Opin Nephrol Hypertens 2002;11:267-72.
9. Sarnak JA, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005;142:342-51.
10. Siewert-Delle A, Ljungman S, Andersson OK, Wilhelmsen L. Does treated primary hypertension lead to end-stage renal disease? A 20-year follow-up of the Primary Prevention Study in Göteborg, Sweden. Nephrol Dial Transplant 1998;13:3084-90.
11. Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005;165:923-8.
12. Zarif L, Covic A, Iyengar S, Sehgal AR, Sedor JR, Schelling JR. Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. Nephrol Dial Transplant 2000;15:1801-7.
13. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, et al, for the African American Study of Kidney Disease and Hypertension Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomised controlled trial. JAMA 2001;285:2719-28.
14. Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, et al, for the African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. JAMA 2002;288:2421-31.
15. Toto RB. Hypertensive nephrosclerosis in African Americans. Kidney Int 2003;64:2331-41.
16. Marin R, Fernández-Vega F, Gorostidi M, Ruilope LM, Díez M, et al. Blood pressure control in patients with chronic renal insufficiency in Spain: a cross-sectional study. J Hypertens 2006;24:395-402.
17. Vikse BE, Aasarød K, Bostad L, Iversen BM. Clinical prognostic factors in biopsy-proven benign nephrosclerosis. Nephrol Dial Transplant 2003;18:517-23.
18. Verhave JC, Hillege HL, Burgerhof JG, Gansevoort RT, De Zeeuw D, De Jong PE; PREVEND study group. The association between atherosclerotic risk factors and renal function in the general population. Kidney Int 2005;67:1967-73.
19. Tracy ER, Strong JP, Newman WP III, Malcom GT, Oalmann MC, Guzman MA. Renovasculopathies of nephrosclerosis in relation to atherosclerosis at ages 25 to 54 years. Kidney Int 1996;49:564-70.
20. Appel LJ, Wright JT Jr, Greene T, Kusek JW, Lewis JB, et al. Longterm effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med 2008;168:832-9.
21. Norris KC, Greene T, Kopple J, Lea J, Lewis J, et al. Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. J Am Soc Nephrol 2006;17:2928-36.
22. Hallan SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009;20:1069-77.
23. Segura J, Campo C, Gil P, Roldán C, Vigil L, Rodicio JL, et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004;15:1616-22.
24. Wright JR, Duggal A, Thomas R, Reeve R, Roberts IS, Kalra PA. Clinicopathological correlation in biopsy-proven atherosclerotic nephropathy: implications for renal functional outcome in atherosclerotic renovascular disease. Nephrol Dial Transplant 2001;16:765-70.
25. Levin A, Djurdjev O, Barrett B, Burgess E, Carlisle E, et al. Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis 2001;38:1398-407.
26. McClellan WM, Langston RD, Presley R. Medicare patients with cardiovascular disease has a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. J Am Soc Nephrol 2004;15:1912-9.
27. Menon V, Sarnak MJ. The epidemiology of chronic kidney disease stages 1 to 4 and cardiovascular disease: a high-risk combination. Am J Kidney Dis 2005;45:223-32.
28. Hillege HL, Van Gilst WH, Van Veldhuisen DJ, Navis G, Grobbee DE, et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 2003;24:412-20.
29. Elsayed EF, Tighiouart H, Griffith J, Kurth T, Levey AS, et al. Cardiovascular disease and subsequent kidney disease. Arch Intern Med 2007;167:1130-6.
30. Marín R, Fernández-Vega F, Díez Ojea B, Alcoy E, Palencia A, et al. Marcadores de progresión de enfermedad renal crónica en pacientes con con nefroesclerosis. Datos evolutivos. Estudio PRONEFROS. Nefrologia 2008;28(Supl 4):48.
31. Hostetter TH. Chronic kidney disease predicts cardiovascular disease. N Engl J Med 2004;351:1344-6.
32. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004;44:642-50.
33. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006;47:51-9.
34. Feig DI, Kang DH, Johnson J. Uric acid and cardiovascular risk. N Engl J Med 2008;359:1811-21.
35. Fernández-Llama P, Poch E, Oriola J, Botey A, Coll E, et al. Angiotensin converting enzyme gene I/D polymorphism in essential hypertension and nephroangiosclerosis. Kidney Int 1998;53:1743-7.
36. Mallamaci F, Zuccalà A, Zoccali C, Testa A, Gaggi R, et al. The deletion polymorphism of the angiotensin-converting enzyme is associated with nephroangioesclerosis. Am J Hypertens 2000;13:433-7.
37. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008;40:1185-92.
38. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, et al. MYH9 is a major-effect risk gene for focal segmental glomeruloesclerosis. Nat Genet 2008;40:1175-84.
39. Freedman BI, Hicks PJ, Bostrom MA, Cunningham ME, Liu Y, et al. Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int 2009;75:736-45.
40. Freedman BI, Kopp JB, Winkler CA, Nelson GW, Rao DC, et al. Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: the HyperGEN study. Am J Nephrol 2009;29:626-32.
41. Freedman BI, Hicks PJ, Bostrom MA, Comeau ME, Divers J, et al. Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD. Nephrol Dial Transplant 2009;24:3366-71.
42. Behar DM, Rosset S, Tzur S, Selig S, Yudkovsky G, et al. African ancestry allelic variation at the MYH9 gene contributes to increased susceptibility to non-diabetic end-stage kidney disease in Hispanic Americans. Hum Mol Genet 2010;19:1816-27.
43. Wang G, Lai FM, Kwan BC, Lai KB, Chow KM, Li PK, Szeto CC. Podocyte Loss in Human Hypertensive Nephrosclerosis. Am J Hypertens 2009;22:300-6.
44. Murea M, Freedman BI. Essential hypertension and risk of nephropathy: a reappraisal. Curr Opin Nephrol Hypertens 2010;19:235-41.
45. Singh N, Nainani N, Arora P, Venuto RC. CKD in MYH9-Related Disorders. Am J Kidney Dis 2009;54:732-40.
46. Rao M, Balakrishnan VS. The genetic basis of kidney disease risk in African Americans: MYH9 as a new candidate gene. Am J Kidney Dis 2009;53:579-83.
47. Divers J, Freedman BI. Susceptibility genes in common complex kidney disease. Curr Opin Nephrol Hypertens 2010;19:79-84.
48. Freedman BI, Sedor JR. Hypertension-associated kidney disease: perhaps no more. J Am Soc Nephrol 2008;19:2047-51.
49. Pattaro C, Aulchenko YS, Isaacs A, Vitart V, Hayward C, Franklin CS, et al. Genome-wide linkage analysis of serum creatinine in three isolated European populations. Kidney Int 2009;76:297-306.